Trifluridine/Tipiracil Application Scope

LONSURF is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have previously received, or are not candidates for, standard therapies including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, if RAS wild-type, anti-EGFR treatment. It is designed to slow disease progression, improve survival outcomes, and provide a therapeutic option for patients with advanced, difficult-to-treat colorectal cancer.

Trifluridine/Tipiracil Characteristics

Ingredients: Trifluridine, Tipiracil
Properties: Oral antineoplastic combination; trifluridine inhibits DNA synthesis, tipiracil prevents trifluridine degradation
Packaging Specification: 15 mg/6.14 mg × 20 tablets/box
Storage: Store in a cool, dry place, away from light
Expiry Date: See packaging
Executive Standard: Drug Registration Regulations
Approval Number: NMPA H20180001
Date of Revision: June 2022
Manufacturer: Taiho Pharmaceutical

Guidelines for the Use of Lonsurf

Dosage and Administration
- Missed Dose: If a dose is missed, take as soon as possible. Do not double the next dose.
Adverse Reactions:
- Common Adverse Reactions (≥5%):
  - nausea, vomiting, decreased blood counts, fatigue
- Serious Adverse Reactions:
  - severe myelosuppression, hypersensitivity reactions
Contraindications: Patients with known severe hypersensitivity to Trifluridine, Tipiracil, or excipients
Precautions:
- Monitor blood counts during treatment
- Advise patients to inform healthcare provider if pregnant, planning pregnancy, or breastfeeding

Trifluridine/Tipiracil Interactions

Consult healthcare provider for potential drug interactions

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.